There is lot to digest in your post Bedger.
I don't agree with some of your points/points though, they might reflect your understanding/opinion or your way of explaining Cook and Perdums stages of tendinopathy.
I understand that this might be your way of explaining it to others In this forum as a result.
You do know your stuff considering you are not a health/ medical professional (does someone consult you on this, if not I am impressed at your dedication to research this).
Rotator cuff tendinopathy is my bread and butter. I will make another post regarding the current treatments for rotator cuff tendinopathy/partial tears and the treatment for degenerative tendinopathy, which as you mentioned has more recently been shown to have a high failure rate.
I mentioned earlier that UTC scans should be used as an outcome measure for ATI as this would be the GOLD standard test to assess the efficacy of ATI in changing the Tendon structure. Cook and Perdum are big fans of this and have used the UTC scan for the "Don't treat the hole, treat the donut" methodology for non-surgical management for degenerative tendons.
I look forward to discussing this further.
Just so everyone is aware, I am a small (3k) holder of OCC who is only on board because of celgro and have questioned ATI and it's efficacy because I am a specialist Physiotherapist who works in this exact field. I just want better research methodology for their trials with a control group and a gold standard outcome measure so we can find out if it actually works. If not, all in on celgro.
- Forums
- ASX - By Stock
- Reminder - J&J ATI Rotator Cuff clinical trial update coming soon
There is lot to digest in your post Bedger. I don't agree with...
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
66.5¢ |
Change
-0.020(2.92%) |
Mkt cap ! $159.0M |
Open | High | Low | Value | Volume |
67.0¢ | 67.0¢ | 65.0¢ | $245.7K | 371.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15000 | 65.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
66.5¢ | 12621 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15000 | 0.655 |
1 | 20123 | 0.650 |
2 | 14260 | 0.645 |
8 | 98811 | 0.640 |
4 | 33664 | 0.635 |
Price($) | Vol. | No. |
---|---|---|
0.665 | 12621 | 2 |
0.670 | 11000 | 1 |
0.675 | 6000 | 1 |
0.680 | 26000 | 2 |
0.690 | 33653 | 3 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online